Brokerages Anticipate Endo International plc (NASDAQ:ENDP) to Announce -$0.15 EPS

Analysts expect Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) to announce ($0.15) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Endo International’s earnings, with estimates ranging from ($0.17) to ($0.13). Endo International posted earnings of $0.65 per share in the same quarter last year, which suggests a negative year over year growth rate of 123.1%. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Endo International will report full year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.70 to $0.85. For the next fiscal year, analysts anticipate that the company will report earnings of $0.29 per share, with EPS estimates ranging from ($0.02) to $0.54. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Endo International.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last announced its quarterly earnings data on Thursday, May 5th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.22. The firm had revenue of $652.26 million during the quarter, compared to the consensus estimate of $637.09 million. Endo International had a negative return on equity of 72.22% and a negative net margin of 24.82%. The business’s revenue for the quarter was down 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS.

ENDP has been the subject of several research reports. Zacks Investment Research downgraded Endo International from a “hold” rating to a “strong sell” rating and set a $2.50 price target for the company. in a research note on Wednesday, February 9th. TheStreet downgraded Endo International from a “c-” rating to a “d” rating in a research note on Wednesday, February 2nd. Piper Sandler downgraded Endo International from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $3.00 to $1.00 in a research note on Friday, May 6th. BMO Capital Markets cut their target price on Endo International from $4.00 to $2.00 in a research note on Monday, May 9th. Finally, Barclays cut their target price on Endo International from $2.00 to $1.00 in a research note on Monday, May 9th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Endo International presently has an average rating of “Hold” and an average target price of $4.07.

NASDAQ:ENDP traded up $0.07 during trading on Friday, reaching $1.20. The company’s stock had a trading volume of 5,436,192 shares, compared to its average volume of 6,483,271. The firm has a market cap of $282.13 million, a price-to-earnings ratio of -0.38 and a beta of 1.07. The firm has a 50 day moving average of $2.21 and a 200-day moving average of $3.49. Endo International has a 12 month low of $1.06 and a 12 month high of $7.07.

Large investors have recently bought and sold shares of the stock. Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Endo International by 34.0% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 438,499 shares of the company’s stock worth $1,013,000 after buying an additional 111,380 shares during the period. State of Tennessee Treasury Department boosted its position in Endo International by 44.5% during the 1st quarter. State of Tennessee Treasury Department now owns 217,468 shares of the company’s stock valued at $502,000 after acquiring an additional 66,966 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Endo International by 161.7% in the 1st quarter. New York State Common Retirement Fund now owns 426,139 shares of the company’s stock worth $984,000 after purchasing an additional 263,322 shares in the last quarter. Sterling Investment Advisors Ltd. boosted its position in shares of Endo International by 36.3% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 37,515 shares of the company’s stock worth $87,000 after purchasing an additional 10,000 shares in the last quarter. Finally, First Quadrant LLC CA purchased a new position in Endo International in the 1st quarter worth $36,000. Institutional investors own 80.39% of the company’s stock.

Endo International Company Profile (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Read More

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.